Nebcina (Tobramycin)
Aminoglycoside Antibiotic for Serious Bacterial Infections
Quick Facts About Nebcina
Key Takeaways About Nebcina (Tobramycin)
- Hospital-administered antibiotic: Nebcina is given by injection or intravenous infusion in a hospital setting by healthcare professionals, not taken at home as a tablet
- Effective against Gram-negative bacteria: Tobramycin is particularly potent against Pseudomonas aeruginosa, Escherichia coli, Klebsiella, and other serious Gram-negative pathogens
- Risk of hearing and kidney damage: Tobramycin can cause irreversible ototoxicity (hearing loss, tinnitus, balance problems) and nephrotoxicity (kidney damage), requiring careful monitoring during treatment
- Therapeutic drug monitoring is essential: Blood levels of tobramycin must be measured regularly to ensure the dose is effective yet safe, particularly peak and trough concentrations
- Special role in cystic fibrosis: Inhaled tobramycin (Tobi, Bramitob) is a cornerstone treatment for chronic Pseudomonas aeruginosa lung infections in cystic fibrosis patients
What Is Nebcina and What Is It Used For?
Nebcina contains tobramycin, an aminoglycoside antibiotic that kills bacteria by irreversibly binding to their ribosomes and disrupting protein synthesis. It is used to treat serious, potentially life-threatening bacterial infections in hospital settings, including pneumonia, severe urinary tract infections, intra-abdominal infections, and endocarditis.
Tobramycin belongs to the aminoglycoside class of antibiotics, a group of potent bactericidal agents that have been a cornerstone of antimicrobial therapy since the 1960s. Tobramycin was first isolated from Streptomyces tenebrarius and has been in clinical use since 1975. It is included on the World Health Organization's List of Essential Medicines, reflecting its critical role in treating serious infections worldwide.
The mechanism of action of tobramycin involves irreversible binding to the 30S ribosomal subunit of susceptible bacteria. This binding disrupts the bacterial protein synthesis machinery, causing misreading of messenger RNA and ultimately leading to the production of abnormal, non-functional proteins. This process is bactericidal, meaning tobramycin actively kills bacteria rather than merely inhibiting their growth. Importantly, tobramycin exhibits concentration-dependent killing, meaning that higher concentrations produce more rapid and complete bacterial killing, and a post-antibiotic effect, where bacterial growth remains suppressed even after the drug concentration falls below the minimum inhibitory concentration (MIC).
Tobramycin is primarily effective against aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Proteus species, Enterobacter species, Serratia marcescens, Acinetobacter species, and Citrobacter species. It is particularly valued for its excellent activity against Pseudomonas aeruginosa, where it is often more potent than gentamicin. Tobramycin has limited activity against Gram-positive organisms and is not effective against anaerobic bacteria.
Nebcina is used to treat the following types of serious infections:
- Lower respiratory tract infections (pneumonia) – particularly hospital-acquired and ventilator-associated pneumonia caused by Gram-negative bacteria, often in combination with a beta-lactam antibiotic
- Severe urinary tract infections – complicated pyelonephritis and urosepsis that do not respond to first-line antibiotics or are caused by multi-resistant organisms
- Intra-abdominal infections – peritonitis, biliary tract infections, and post-surgical abdominal infections, usually in combination with agents active against anaerobes
- Endocarditis – heart valve infections, particularly those caused by Pseudomonas aeruginosa or enterococci, in combination with other antibiotics
- Septicaemia (bloodstream infections) – severe sepsis caused by susceptible Gram-negative organisms
- Bone and joint infections – osteomyelitis and septic arthritis caused by susceptible organisms
In addition to the injectable formulation, tobramycin is available as a nebuliser solution (marketed as Tobi and Bramitob) for inhalation therapy in patients with cystic fibrosis who have chronic Pseudomonas aeruginosa lung colonisation. Inhaled tobramycin delivers high concentrations directly to the lungs while minimising systemic toxicity. This route of administration has been shown to improve lung function, reduce bacterial burden, and decrease the frequency of respiratory exacerbations in cystic fibrosis patients. The European Cystic Fibrosis Society recommends inhaled tobramycin as a first-line treatment for chronic Pseudomonas infection.
What Should You Know Before Receiving Nebcina?
Before receiving Nebcina, inform your doctor about any kidney disease, hearing problems, neuromuscular disorders, dehydration, or if you or your family have a history of mitochondrial mutations. Tobramycin carries significant risks of kidney damage and hearing loss, particularly in vulnerable patients.
Contraindications
You should not receive Nebcina if any of the following apply to you:
- Allergy to tobramycin or any other aminoglycoside antibiotic (such as gentamicin, amikacin, or streptomycin) – cross-sensitivity between aminoglycosides is well documented
- Allergy to any of the excipients in Nebcina, including sodium metabisulphite, which can cause severe hypersensitivity reactions and bronchospasm in susceptible individuals, particularly those with asthma
- Myasthenia gravis – aminoglycosides can worsen neuromuscular blockade and are generally contraindicated in this condition unless no safer alternative exists
Warnings and Precautions
Talk to your doctor before receiving Nebcina if you have or have had any of the following conditions. These factors significantly influence the risk of serious adverse effects:
- Kidney disease or impaired renal function – tobramycin is excreted almost entirely by the kidneys, so any reduction in kidney function leads to drug accumulation and increased toxicity risk. Dose adjustments are essential
- Hearing problems including tinnitus (ringing in the ears), hearing loss, or vestibular disturbances – pre-existing damage to the auditory or vestibular system increases the risk of irreversible ototoxicity
- Neuromuscular disorders such as myasthenia gravis or Parkinson's disease – aminoglycosides can enhance neuromuscular blockade, potentially causing respiratory paralysis
- Dehydration from any cause, including vomiting, diarrhoea, excessive sweating, or inadequate fluid intake – dehydration concentrates tobramycin in the blood and kidneys, increasing nephrotoxicity risk
- Mitochondrial mutations – if you or anyone in your family has a mitochondrial mutation disease or hearing loss caused by aminoglycoside antibiotics, you may be at significantly increased risk of permanent hearing loss. The most common mutation associated with aminoglycoside ototoxicity is the m.1555A>G mutation in the mitochondrial 12S rRNA gene
- Elderly patients – age-related decline in kidney function increases the risk of nephrotoxicity and ototoxicity, even when serum creatinine appears normal
- Burns patients – altered pharmacokinetics in patients with extensive burns may require higher doses and more frequent monitoring
Tobramycin can cause irreversible damage to your kidneys (nephrotoxicity) and hearing/balance organs (ototoxicity). You will be closely monitored during treatment with regular blood tests, hearing assessments, and kidney function tests. The risk of toxicity increases with higher doses, longer treatment duration, repeated courses, and concurrent use of other nephrotoxic or ototoxic drugs. Report any changes in hearing, balance, or urine output to your medical team immediately.
Pregnancy and Breastfeeding
If you are pregnant, think you might be pregnant, or are planning to become pregnant, tell your doctor before receiving Nebcina. Tobramycin crosses the placenta and can reach the foetus. There have been reports of irreversible bilateral hearing loss in children whose mothers received aminoglycoside antibiotics during pregnancy. While the exact risk with tobramycin is not fully established, the potential for foetal harm means it should only be used during pregnancy when the potential benefits clearly outweigh the risks and no safer alternative is available.
Tobramycin is excreted in breast milk in small amounts. The low oral bioavailability of aminoglycosides means that significant systemic absorption by the breastfed infant is unlikely. However, there is a theoretical risk of effects on the infant's gut flora. Your doctor will weigh the benefits of breastfeeding and the benefits of your treatment when advising you. The WHO and the American Academy of Pediatrics generally consider aminoglycosides to be compatible with breastfeeding.
Driving and Operating Machinery
Nebcina is usually administered in a hospital setting, so driving and operating machinery are unlikely to be relevant during treatment. However, tobramycin can cause side effects such as confusion, disorientation, dizziness, vertigo, and drowsiness, which could impair your ability to drive or operate machinery. Do not drive or use machines if you experience any of these effects after discharge from hospital. Wait until these symptoms have fully resolved before resuming such activities.
Important Information About Excipients
Nebcina contains sodium metabisulphite, which can in rare cases cause severe hypersensitivity reactions and bronchospasm. This is particularly relevant for patients with asthma or a history of sulphite sensitivity. The product also contains sodium, but in amounts less than 1 mmol (23 mg) per ml, and is therefore considered essentially sodium-free.
How Does Nebcina Interact with Other Drugs?
Tobramycin interacts with several important drug classes. The most dangerous interactions involve other nephrotoxic or ototoxic medications, which can dramatically increase the risk of kidney damage and hearing loss. Neuromuscular blocking agents can also interact dangerously with tobramycin.
Drug interactions with tobramycin are clinically significant and can be life-threatening. The two major categories of concern are drugs that increase the risk of nephrotoxicity/ototoxicity and drugs that enhance neuromuscular blockade. Always inform your medical team about all medications you are currently receiving, including prescription medicines, over-the-counter products, and herbal supplements.
Major Interactions
| Drug / Drug Class | Interaction | Clinical Significance |
|---|---|---|
| Loop diuretics (furosemide, bumetanide, ethacrynic acid) | Increased risk of ototoxicity and nephrotoxicity; diuretics may also alter aminoglycoside pharmacokinetics | Avoid combination if possible. If essential, monitor hearing and renal function closely |
| Other aminoglycosides (gentamicin, amikacin, streptomycin) | Additive nephrotoxicity and ototoxicity; no therapeutic benefit from combining aminoglycosides | Contraindicated – never combine two aminoglycosides |
| Amphotericin B | Synergistic nephrotoxicity; both drugs independently cause significant kidney damage | Avoid if possible. Monitor renal function daily if combination is necessary |
| Vancomycin | Increased risk of nephrotoxicity and potentially ototoxicity | Common combination in clinical practice; requires close monitoring of drug levels and renal function |
| Cisplatin and other platinum-based chemotherapy | Markedly increased risk of both nephrotoxicity and ototoxicity | Avoid combination. If unavoidable, extend monitoring period as cisplatin toxicity may be delayed |
| Neuromuscular blocking agents (suxamethonium, rocuronium, atracurium) | Enhanced and prolonged neuromuscular blockade, potentially causing respiratory paralysis | Use with extreme caution; ensure availability of mechanical ventilation and reversal agents |
| Ciclosporin (cyclosporine) | Increased risk of nephrotoxicity due to both drugs' renal toxicity profiles | Monitor renal function closely; consider alternative antibiotic if possible |
Other Notable Interactions
Several additional drug interactions deserve attention when tobramycin is being administered:
- Non-steroidal anti-inflammatory drugs (NSAIDs) – may reduce kidney blood flow and increase tobramycin accumulation
- Cephalosporins (particularly cephalothin) – potential additive nephrotoxicity, though combination therapy with certain cephalosporins is common practice
- Penicillins – in vitro inactivation of tobramycin can occur if mixed in the same infusion bag. Administer separately
- Bisphosphonates (alendronate, zoledronic acid) – potential additive risk of electrolyte disturbances including hypocalcaemia
- Anticoagulants – tobramycin may enhance the effect of warfarin and other coumarin anticoagulants; monitor INR
Despite the interaction risks, tobramycin is frequently used in combination with beta-lactam antibiotics (penicillins, cephalosporins, carbapenems) to achieve synergistic bactericidal activity, particularly against Pseudomonas aeruginosa and enterococcal infections. This combination exploits different mechanisms of action: the beta-lactam disrupts the bacterial cell wall, allowing greater aminoglycoside penetration. When used together, the drugs must always be administered separately and never mixed in the same infusion line.
What Is the Correct Dosage of Nebcina?
Nebcina dosing is determined by your doctor based on body weight, kidney function, severity of infection, and therapeutic drug monitoring results. The standard dose for adults is 3–5 mg/kg per day, given either as a single daily dose (extended-interval dosing) or divided into two to three doses every 8–12 hours.
Tobramycin dosing is complex and must be individualised for each patient. There are two main dosing strategies: conventional (multiple daily dosing) and extended-interval (once-daily dosing). Extended-interval dosing has become the preferred approach in many institutions because it optimises the concentration-dependent killing effect and post-antibiotic effect of aminoglycosides while potentially reducing nephrotoxicity.
Adults
Extended-Interval Dosing (Once-Daily – Preferred)
5–7 mg/kg administered intravenously once every 24 hours. This approach exploits the concentration-dependent killing of tobramycin and the post-antibiotic effect. Dose adjustments are based on measured drug levels and kidney function. The Infectious Diseases Society of America (IDSA) and many international guidelines support this dosing strategy for most indications.
Conventional Dosing (Multiple Daily Doses)
3–5 mg/kg/day divided into equal doses every 8 hours (i.e., 1–1.7 mg/kg every 8 hours). This older approach is still used in certain clinical situations, including endocarditis, pregnancy, burns patients, and patients with significantly impaired renal function where once-daily dosing is not appropriate.
Children
Paediatric Dosing
Children and adolescents typically require higher mg/kg doses than adults due to larger volumes of distribution and faster clearance. The usual dose is 6–7.5 mg/kg/day for extended-interval dosing. For conventional dosing, the standard range is 6–7.5 mg/kg/day divided into three equal doses every 8 hours. Neonates require special dosing protocols based on gestational age, postnatal age, and weight, with typical doses of 4–5 mg/kg every 24–48 hours.
Elderly Patients
Elderly patients often require dose reduction due to age-related decline in kidney function, even when serum creatinine levels appear normal. This is because serum creatinine may not accurately reflect renal function in elderly patients with reduced muscle mass. Estimated glomerular filtration rate (eGFR) or creatinine clearance (calculated using the Cockcroft-Gault formula) should guide dosing in this population. More frequent therapeutic drug monitoring is recommended.
Dose Adjustment in Renal Impairment
| Creatinine Clearance | Dosing Interval | Notes |
|---|---|---|
| >80 ml/min (normal) | Every 24 hours (EID) or every 8 hours (conventional) | Standard dosing; monitor levels |
| 40–80 ml/min (mild–moderate impairment) | Every 12–24 hours | Reduce dose or extend interval based on levels |
| 20–40 ml/min (moderate–severe impairment) | Every 24–48 hours | Significant dose reduction; frequent level monitoring |
| <20 ml/min (severe impairment) | Every 48–72 hours | Consider alternative antibiotics; dose based on levels |
| Haemodialysis | After each dialysis session | Tobramycin is dialysable; supplemental dose after dialysis |
Missed Dose
Since Nebcina is administered by healthcare professionals in a hospital setting, missed doses are extremely unlikely. However, if a dose is delayed or omitted for any reason, your medical team will determine the appropriate course of action based on your current drug levels, kidney function, and clinical status. Do not attempt to “double up” on doses to compensate for a missed one.
Overdose
Because Nebcina is given by healthcare professionals, overdose is rare but can occur, particularly in patients with rapidly changing kidney function. Signs of tobramycin overdose include dizziness, tinnitus, hearing loss, respiratory distress, and reduced urine output. In the event of overdose, treatment is primarily supportive. Tobramycin can be removed from the body by haemodialysis, which is the treatment of choice in severe overdose. Peritoneal dialysis is less effective. There is no specific antidote for aminoglycoside toxicity.
Therapeutic drug monitoring is a critical component of tobramycin therapy. For conventional dosing, both peak levels (drawn 30 minutes after IV infusion completion; target 4–10 mg/L for most infections, up to 12 mg/L for life-threatening infections) and trough levels (drawn just before the next dose; target <2 mg/L) are measured. For extended-interval dosing, a single level drawn 6–14 hours post-dose is typically used with a nomogram (e.g., Hartford nomogram) to guide dosing adjustments. The goal is to maximise bactericidal activity while minimising the risk of toxicity.
What Are the Side Effects of Nebcina?
Like all antibiotics, tobramycin can cause side effects. The most serious are damage to the inner ear (ototoxicity) and kidneys (nephrotoxicity). These risks are dose-related and increase with longer treatment duration and concurrent use of other toxic medications. Contact your medical team immediately if you notice any changes in hearing, balance, or urine output.
The side effects of tobramycin are well characterised from decades of clinical use. The most clinically important adverse effects are ototoxicity and nephrotoxicity, both of which can be irreversible. The frequency and severity of side effects depend on several factors, including the dose, duration of treatment, patient's kidney function, age, state of hydration, and concurrent medications.
Signs of inner ear or hearing nerve damage (common in patients with impaired kidney function, less common in patients with normal kidney function): vertigo, dizziness, whistling or buzzing sounds in the ears, hearing loss, numbness, tingling, muscle twitching, or convulsions. Signs of worsening kidney function: decreased urine volume. Signs of severe allergic reaction: skin rash with blisters and sores in the mouth and eyes (Stevens-Johnson syndrome), widespread skin peeling (toxic epidermal necrolysis). Severe diarrhoea that may indicate Clostridioides difficile infection.
Common Side Effects
- Increased eosinophil count (a type of white blood cell)
- Vasculitis (inflammation of blood vessels)
- Elevated liver enzymes (AST, ALT)
- Pain and local reactions at the injection site
Uncommon Side Effects
- Headache
- Nausea and vomiting
- Elevated bilirubin and liver enzymes (alkaline phosphatase, lactate dehydrogenase)
- Allergic skin rash, urticaria (hives), itching
Rare Side Effects
- Anaemia (low red blood cell count)
- Leucopenia (low white blood cell count)
- Low platelet count (thrombocytopenia)
- Confusion and disorientation
- Diarrhoea
- Fever and drowsiness
- Low blood levels of calcium, magnesium, sodium, and potassium
Frequency Not Known
- Oral and genital fungal infections (candidiasis)
- Stevens-Johnson syndrome (severe skin and mucous membrane reaction)
- Exfoliative dermatitis (widespread skin peeling)
- Toxic epidermal necrolysis (severe, life-threatening skin reaction)
- Clostridioides difficile-associated diarrhoea
Ototoxicity in Detail
Ototoxicity is the most feared adverse effect of aminoglycoside therapy. Tobramycin can damage both the cochlear (hearing) and vestibular (balance) systems of the inner ear. Cochlear toxicity manifests as tinnitus (ringing or buzzing in the ears), high-frequency hearing loss (initially may be detected only by audiometry), and in severe cases, complete deafness. Vestibular toxicity presents as dizziness, vertigo, nystagmus (involuntary eye movements), and difficulty with balance and coordination.
The risk of ototoxicity is increased by higher cumulative doses, longer treatment duration, concurrent use of other ototoxic drugs (particularly loop diuretics and cisplatin), pre-existing hearing impairment, renal impairment, and genetic susceptibility (mitochondrial mutations, particularly the m.1555A>G mutation). Importantly, ototoxicity may not become apparent until days to weeks after treatment has ended, and it is often irreversible. Baseline and serial audiometric testing is recommended for patients receiving tobramycin for more than 5–7 days.
Nephrotoxicity in Detail
Tobramycin is nephrotoxic, meaning it can damage the kidneys. The primary mechanism involves accumulation of the drug in the proximal tubular cells of the kidney, leading to cellular injury and acute tubular necrosis. Early signs include increased urinary excretion of brush-border enzymes and beta-2 microglobulin, followed by rising serum creatinine and blood urea nitrogen (BUN), and reduced urine output.
Nephrotoxicity occurs in approximately 10–25% of patients receiving aminoglycosides, depending on the definition used and the patient population. Risk factors include pre-existing renal impairment, advanced age, dehydration, hypotension, concurrent nephrotoxic drugs, and prolonged treatment courses. The good news is that aminoglycoside-induced nephrotoxicity is usually reversible if detected early and the drug is discontinued or the dose adjusted. Kidney function typically recovers within days to weeks of stopping treatment. Regular monitoring of serum creatinine and urea is mandatory during tobramycin therapy.
How Should You Store Nebcina?
Store Nebcina out of the sight and reach of children. Do not use after the expiry date printed on the packaging. In hospital settings, storage and preparation are managed by pharmacy and nursing staff according to established protocols.
Nebcina injection solution should be stored according to the following guidelines:
- Temperature: Store at room temperature (15–25°C). Do not freeze
- Light protection: Keep the ampoules in the outer carton to protect from light
- Expiry date: Do not use Nebcina after the expiry date stated on the carton and ampoule label. The expiry date refers to the last day of that month
- After opening: Nebcina ampoules are for single use only. Any unused solution should be discarded immediately after opening
- Visual inspection: Before use, the solution should be inspected visually. Nebcina is a clear, colourless solution. Do not use if the solution appears cloudy, discoloured, or contains particles
Medicines should not be disposed of via wastewater or household waste. In hospital settings, unused medicines are disposed of according to institutional protocols for pharmaceutical waste. For patients receiving inhaled tobramycin at home, ask your pharmacist about proper disposal of used nebuliser cartridges and expired medications. These measures help to protect the environment.
What Does Nebcina Contain?
The active substance in Nebcina is tobramycin. Each millilitre of Nebcina 40 mg/ml contains 40 mg of tobramycin, while each millilitre of Nebcina 80 mg/ml contains 80 mg of tobramycin. The inactive ingredients are sodium edetate, sodium metabisulphite, sulphuric acid (for pH adjustment), and water for injections.
Active Ingredient
Tobramycin is a naturally occurring aminoglycoside antibiotic originally isolated from Streptomyces tenebrarius. Its chemical formula is C18H37N5O9 and it has a molecular weight of 467.52 g/mol. Tobramycin is freely soluble in water and practically insoluble in organic solvents. It is chemically related to other aminoglycosides such as gentamicin, amikacin, and kanamycin.
Inactive Ingredients (Excipients)
- Sodium edetate (disodium EDTA) – a chelating agent used as a stabiliser to prevent degradation of the active ingredient by binding metal ions
- Sodium metabisulphite – an antioxidant preservative. Can cause allergic reactions, including anaphylaxis and bronchospasm, in susceptible individuals
- Sulphuric acid – used for pH adjustment to ensure the solution is within the optimal pH range for stability and tolerability
- Water for injections – the sterile solvent base
Packaging and Appearance
Nebcina is a clear, colourless solution for injection packaged in glass ampoules. Available pack sizes include:
- Nebcina 40 mg/ml: 10 ampoules of 2 ml (80 mg per ampoule), or 10 × 10 ampoules of 2 ml
- Nebcina 80 mg/ml: 10 ampoules of 2 ml (160 mg per ampoule)
Not all pack sizes may be marketed in your country. The marketing authorisation holder is Viatris, and the product is manufactured by Vianex S.A. in Greece.
Frequently Asked Questions About Nebcina
While Nebcina (tobramycin) and gentamicin are both aminoglycoside antibiotics with similar mechanisms of action, tobramycin is generally more potent against Pseudomonas aeruginosa, making it the preferred choice for infections caused by this organism. Gentamicin has slightly broader Gram-negative coverage and is often preferred for empirical therapy of unknown infections. Both drugs carry similar risks of ototoxicity and nephrotoxicity, though some studies suggest tobramycin may be slightly less nephrotoxic than gentamicin at equivalent doses. The choice between them is typically guided by local resistance patterns and the suspected or confirmed pathogen.
No, tobramycin (Nebcina) for systemic infections is not available as an oral tablet. Aminoglycosides are very poorly absorbed from the gastrointestinal tract, which is why they must be given by injection (intramuscular or intravenous) to treat systemic infections. This administration is performed in a hospital setting by healthcare professionals. However, tobramycin is available as an inhaled form (nebuliser solution) for cystic fibrosis patients to use at home, and as eye drops for bacterial eye infections.
Blood tests during tobramycin treatment serve two critical purposes. First, therapeutic drug monitoring (TDM) measures the concentration of tobramycin in your blood to ensure the dose is high enough to kill the bacteria but low enough to minimise the risk of toxicity. Peak levels indicate whether the dose is sufficient for bacterial killing, while trough levels indicate whether the drug is being cleared adequately between doses. Second, regular kidney function tests (serum creatinine, urea) and electrolyte levels are checked to detect early signs of nephrotoxicity. Early detection allows dose adjustment or discontinuation before irreversible damage occurs.
Tobramycin carries a risk of ototoxicity (hearing damage) that is increased in patients with pre-existing hearing problems. If you have any degree of hearing impairment, tinnitus, or balance problems, your doctor will carefully weigh the benefits of tobramycin treatment against the risk of worsening your hearing. In some cases, an alternative antibiotic may be chosen. If tobramycin is essential, more frequent audiometric monitoring will be performed, and the treatment course will be kept as short as possible. Patients with mitochondrial mutations (particularly m.1555A>G) are at especially high risk and should generally avoid aminoglycosides.
A typical course of Nebcina treatment for most infections lasts 7 to 10 days. However, the duration can vary depending on the type and severity of infection and your clinical response. Complicated infections such as endocarditis or osteomyelitis may require longer courses, while uncomplicated urinary tract infections may be treated with shorter courses. Your doctor will aim for the shortest effective treatment duration to minimise the risk of nephrotoxicity and ototoxicity. For inhaled tobramycin in cystic fibrosis, treatment cycles of 28 days on followed by 28 days off are standard.
All information on this page is based on international medical guidelines and peer-reviewed research, including the European Medicines Agency (EMA) Summary of Product Characteristics for tobramycin, WHO Model Formulary, British National Formulary (BNF), Infectious Diseases Society of America (IDSA) guidelines on aminoglycoside use, European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, and Cochrane systematic reviews of aminoglycoside dosing strategies. All medical claims are supported by evidence level 1A, the highest quality of evidence based on systematic reviews of randomized controlled trials.
References
- European Medicines Agency (EMA). Tobramycin – Summary of Product Characteristics. EMA. Available at: ema.europa.eu
- World Health Organization. WHO Model Formulary 2023: Tobramycin. WHO. Available at: who.int
- Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clinical Pharmacokinetics. 2009;48(2):71–88. doi:10.2165/0003088-200948020-00001
- Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clinical Infectious Diseases. 2007;45(6):753–760. doi:10.1086/520991
- Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312(7027):338–345. doi:10.1136/bmj.312.7027.338
- Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. American Journal of Respiratory and Critical Care Medicine. 2009;180(9):802–808. doi:10.1164/rccm.200812-1845PP
- Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax. 2010;65(7):654–658. doi:10.1136/thx.2009.131532
- British National Formulary (BNF). Tobramycin. NICE. Available at: bnf.nice.org.uk
- Infectious Diseases Society of America (IDSA). Practice Guidelines for the Diagnosis and Management of Infectious Diseases. IDSA. Available at: idsociety.org
- European Committee on Antimicrobial Susceptibility Testing (EUCAST). Tobramycin Breakpoint Tables. EUCAST. Available at: eucast.org
About This Article
This article was written by the iMedic Medical Editorial Team, a multidisciplinary group of licensed physicians, pharmacists, and medical writers specialising in evidence-based medicine and clinical pharmacology. All content is reviewed according to international medical standards and updated regularly to reflect the latest clinical guidelines and research.
iMedic Medical Editorial Team – Specialists in infectious disease, clinical pharmacology, and antimicrobial therapy with documented academic background and clinical experience.
iMedic Medical Review Board – Independent panel of board-certified physicians and clinical pharmacologists who review all content for accuracy, completeness, and adherence to current clinical guidelines.
Editorial process: All articles undergo a rigorous editorial process including evidence review, expert medical review, fact-checking against primary sources, and regular updates. We follow the GRADE evidence framework and prioritise recommendations from WHO, IDSA, ESCMID, and other internationally recognised bodies. We have no commercial funding and accept no pharmaceutical company sponsorship.